TMCnet - World's Largest Communications and Technology Community



Burns - Pipeline Review, H2 2017 - Research and Markets
[September 13, 2017]

Burns - Pipeline Review, H2 2017 - Research and Markets

The "Burns - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Burns - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio i Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Burns - Overview
  3. Burns - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Burns - Therapeutics Assessment
  10. Assessment by Target (News - Alert)
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Burns - Companies Involved in Therapeutics Development
  • AlgiPharma AS
  • Alliance Pharma Plc
  • Amarantus Bioscience Holdings Inc
  • American Gene Technologies International Inc
  • Anterogen Co Ltd
  • CytoTools AG
  • Destiny Pharma Ltd
  • Lakewood-Amedex Inc
  • Madam Therapeutics BV
  • MediWound Ltd
  • Phagelux Inc
  • Phosphagenics Ltd
  • Se-cure Pharmaceuticals Ltd
  • Stratatech Corp
  • USV Pvt Ltd

For more information about this report visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy